ID   YCUB-2
AC   CVCL_A082
SY   YCUB2; YcuB2; Yokohama City University BCP-ALL-2
DR   DSMZ; ACC-961
DR   IARC_TP53; 28430
DR   Wikidata; Q54995372
RX   PubMed=11417493;
RX   PubMed=19157546;
RX   PubMed=20147975;
RX   PubMed=20519628;
RX   PubMed=20575032;
RX   PubMed=29786757;
RX   PubMed=32144432;
RX   PubMed=35124168;
CC   Population: Japanese.
CC   Doubling time: ~24 hours (DSMZ=ACC-961).
CC   Sequence variation: Gene fusion; HGNC; HGNC:4977; HLF + HGNC; HGNC:11633; TCF3; Name(s)=TCF3-HLF, E2A-HLF (PubMed=11417493).
CC   Sequence variation: Mutation; HGNC; HGNC:7978; NR3C1; Simple; p.Ser395Arg (c.1185C>G); Zygosity=Homozygous (PubMed=35124168).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ=ACC-961
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 9
ST   D18S51: 13
ST   D19S433: 13
ST   D21S11: 29,33.2
ST   D2S1338: 20,23
ST   D3S1358: 17,18
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 14,15
ST   FGA: 21,22
ST   Penta D: 11
ST   Penta E: 11,16
ST   TH01: 7,8
ST   TPOX: 8,9
ST   vWA: 18
DI   NCIt; C199241; B acute lymphoblastic leukemia with TCF3-HLF rearrangement
DI   ORDO; Orphanet_641375; B-lymphoblastic leukemia/lymphoma with t(17;19)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   4Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 14
//
RX   PubMed=11417493; DOI=10.1038/sj.leu.2402120;
RA   Takahashi H., Goto H., Funabiki T., Fujii H., Yamazaki S., Fujioka K.,
RA   Ikuta K., Kai S.;
RT   "Expression of two types of E2A-HLF fusion proteins in YCUB-2, a novel
RT   cell line established from B-lineage leukemia with t(17;19).";
RL   Leukemia 15:995-997(2001).
//
RX   PubMed=19157546; DOI=10.1016/j.leukres.2008.12.003;
RA   Goto H., Naruto T., Tanoshima R., Kato H., Yokosuka T.,
RA   Yanagimachi M., Fujii H., Yokota S., Komine H.;
RT   "Chemo-sensitivity in a panel of B-cell precursor acute lymphoblastic
RT   leukemia cell lines, YCUB series, derived from children.";
RL   Leuk. Res. 33:1386-1391(2009).
//
RX   PubMed=20147975; DOI=10.1038/leu.2010.8;
RA   Akahane K., Inukai T., Inaba T., Kurosawa H., Look A.T., Kiyokawa N.,
RA   Fujimoto J., Goto H., Endo M., Zhang X., Hirose K., Kuroda I.,
RA   Honna H., Kagami K., Goi K., Nakazawa S., Sugita K.;
RT   "Specific induction of CD33 expression by E2A-HLF: the first evidence
RT   for aberrant myeloid antigen expression in ALL by a fusion
RT   transcription factor.";
RL   Leukemia 24:865-869(2010).
//
RX   PubMed=20519628; DOI=10.1182/blood-2009-09-244673;
RA   Hirose K., Inukai T., Kikuchi J., Furukawa Y., Ikawa T., Kawamoto H.,
RA   Oram S.H., Gottgens B., Kiyokawa N., Miyagawa Y., Okita H.,
RA   Akahane K., Zhang X.-C., Kuroda I., Honna H., Kagami K., Goi K.,
RA   Kurosawa H., Look A.T., Matsui H., Inaba T., Sugita K.;
RT   "Aberrant induction of LMO2 by the E2A-HLF chimeric transcription
RT   factor and its implication in leukemogenesis of B-precursor ALL with
RT   t(17;19).";
RL   Blood 116:962-970(2010).
//
RX   PubMed=20575032; DOI=10.1002/ajh.21738; PMCID=PMC7159455;
RA   Inukai T., Zhang X.-R., Kameyama T., Suzuki Y., Yoshikawa K., Kuroda I.,
RA   Nemoto A., Akahane K., Sato H., Goi K., Nakamoto K., Hamada J.-i.,
RA   Tada M., Moriuchi T., Sugita K.;
RT   "A specific linkage between the incidence of TP53 mutations and type
RT   of chromosomal translocations in B-precursor acute lymphoblastic
RT   leukemia cell lines.";
RL   Am. J. Hematol. 85:535-537(2010).
//
RX   PubMed=29786757; DOI=10.1007/s12185-018-2474-7;
RA   Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H.,
RA   Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T.,
RA   Sugita K., Hosoi H.;
RT   "Copy number abnormality of acute lymphoblastic leukemia cell lines
RT   based on their genetic subtypes.";
RL   Int. J. Hematol. 108:312-318(2018).
//
RX   PubMed=32144432; DOI=10.1007/s00280-020-04045-9;
RA   Goto H., Yoshino Y., Ito M., Nagai J.-i., Kumamoto T., Inukai T.,
RA   Sakurai Y., Miyagawa N., Keino D., Yokosuka T., Iwasaki F.,
RA   Hamanoue S., Shiomi M., Goto S.;
RT   "Aurora B kinase as a therapeutic target in acute lymphoblastic
RT   leukemia.";
RL   Cancer Chemother. Pharmacol. 85:773-783(2020).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//